Researchers at The University of Texas MD Anderson Cancer Center have identified a previously unknown pathway that prostate tumors use to suppress the immune system. The work highlights a dual role for the protein B7-H3 in helping tumors evade immune attack, according to the report.
The pathway works by reshaping the tumor microenvironment, making it more resistant to treatment. This discovery offers a clearer explanation for why some prostate cancers do not respond to existing therapies and suggests a specific biological target for intervention.
The study found that a combined targeted therapy approach improved outcomes, though the full details of the regimen were not included in the summary. The findings support further investigation into B7-H3 as a therapeutic target for prostate cancer.